San Diego, United States
Lassen Therapeutics, founded in 2019, is committed to transforming biotechnology and health care through its innovative approach to creating biotherapeutics, aiming to enhance patient outcomes in serious diseases. Their slogan, "Combining innovative science, leading technology, and unmatched know-how to create novel medicines," underscores their mission.
Headquartered in the United States, Lassen Therapeutics operates at the intersection of Biotechnology, Health Care, Health and Wellness, and Life Sciences. This positions the company as a pivotal player in addressing critical health challenges globally.
Their most recent financial milestone was a substantial $85.00M Series B investment on 19 December 2023, reflecting strong confidence from major investors such as Longitude Capital, Alta Partners, BVF Partners, Catalio Capital Management, Frazier Life Sciences, and Longwood Capital Partners. This capital injection underscores their potential to scale and make a significant impact on the biotherapeutics landscape.
